Aimmune Therapeutics — Corporate Update (November 2018)
31 slides from Aimmune Therapeutics's corporate update, Nov 19, 2018
Slide 1: Conference Call for Investment Community
Nov 19, 2018 Conference Call for Investment Community Exhibit 99.2
Slide 2: Agenda for Today's Call
Agenda for Today’s Call Topic Speaker Safe Harbor Statement Laura Hansen, PhD, VP, Investor Relations Opening Remarks Jayson Dallas, MD, President & Chief Executive Officer AR101 for Peanut Allergy NEJM publication of PALISADE RAMSES Topline Results Daniel Adelman, MD, Chief Medical Officer Q&A Jays
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, clinical development plans, anticipated milestones, product candidate benefits, potential market size, product adoption
Slide 4: Aimmune's food allergy treatments are investigational and are not FDA-approved
Aimmune’s food allergy treatments are investigational and are not FDA-approved
Slide 5: PALISADE Phase 3 Results Published in NEJM
PALISADE Phase 3 Results Published in NEJM (Nov 18, 2018) “…treatment with AR101 resulted in higher doses of peanut protein that could be ingested without dose-limiting symptoms and in lower symptom severity during peanut exposure at the exit food challenge than placebo.” Vickery et al., NEJM, Novem
Slide 6: Executive Summary
Executive Summary Aimmune Therapeutics is leading the field in developing novel treatments for food allergies New England Journal of Medicine publication highlights phase 3 PALISADE trial of AR101 Recently completed RAMSES phase 3 safety showed favorable safety profile; consistent with PALISADE In P
Slide 7: Peanut Allergy is One of the Most Common Food Allergies
Peanut Allergy is One of the Most Common Food Allergies 4 out of 10 children with peanut allergy experienced a severe reaction over a 3-year period 8 out of 10 children with peanut allergy never outgrow it Over 1.6 million kids and teens affected in United States
Slide 8: Our Precision Medicine Approach Will Leverage the Oral Route
Our Precision Medicine Approach Will Leverage the Oral Route Characterized allergen profile and FDA-regulated biologic products Convenient, once-daily oral dose taken with spoonfuls of food Research shows high levels of desensitization can be achieved with oral immunotherapy that may not be possible
Slide 9: Aimmune Therapeutics: Leading the Field in Developing Food Allergy Treatments
Aimmune Therapeutics: Leading the Field in Developing Food Allergy Treatments Backed by rigorous science, our approach aims to transform food allergy treatment First-of-its-kind therapy to reduce the frequency and severity of peanut allergy reactions Food allergies are a growing, often life-threaten
Slide 10: PALISADE Was the Largest, Most Rigorous Phase 3 Trial of Immunotherapy for Peanut Allergy
Largest and most rigorously conducted oral immunotherapy trial for peanut allergy ever reported First to use an independent blinded assessor DBPCFC at both baseline and exit First and only peanut OIT study to exceed the pre-specified, FDA-mandated superiority margin for efficacy First to accept part
Slide 11: Participant Disposition
Participant Disposition Safety Population (N=496*) Completer Population (N=412†) *3 were randomized in error; 496 exposed to ≥ 1 dose of study product †2 AR101 and 1 placebo subjects had an evaluable exit DBPCFC but did not complete the study per protocol. Vickery et al., NEJM, November 18, 2018 (on
Slide 12: PALISADE Hit Primary and Secondary Efficacy Endpoints
PALISADE Hit Primary and Secondary Efficacy Endpoints Patients Ages 4-17 Who Tolerated Each Dose Level at Exit DBPCFC *p<0.00001 for Treatment Difference >15% DBPCFC: Double-Blind, Placebo-Controlled Food Challenge Intent-to-Treat Analysis1 Primary Endpoint Key Secondary Endpoints *p<0.00001 Peanut
Slide 13: Response was Consistent Across All Age Groups Studied
Response was Consistent Across All Age Groups Studied Percentage of Patients Who Completed the Trial and Tolerated 600 mg of Peanut Protein at Exit DBPCFC (n=33) (n=131) (n=281) Responders % (n=84) (n=197) (n=99) (n=20) (n=32) (n=13) ITT analysis of adults AR101 41.5% vs Placebo 14.3% (p=0.07) DBPCF
Slide 14: PALISADE Participants Were Highly Atopic
PALISADE Participants Were Highly Atopic Percentage of Participants with Past Medical History Vickery et al., NEJM, November 18, 2018 (online publication)
Slide 15: In an Atopic Population, Adverse Events are Expected
In an Atopic Population, Adverse Events are Expected *Treatment-Emergent Adverse Events (TEAEs) regardless of relatedness to treatment 99% and 95% of AR101 and Placebo participants, respectively, experienced at least 1 TEAE* Vickery et al., NEJM, November 18, 2018 (online publication)
Slide 16: Adverse Events were Mostly Mild or Moderate
0.004 0.005 Number of AR101-Related TEAEs Per Month of Exposure Adverse Events were Mostly Mild or Moderate Vickery et al., NEJM, November 18, 2018 (online publication)
Slide 17: Trigger Foods Cause Allergic Reactions of Different Severities
Trigger Foods Cause Allergic Reactions of Different Severities MILD (Grade 1) Transient skin hive Tingling around the mouth Gastrointestinal discomfort MODERATE (Grade 2) Persistent hives Wheezing Abdominal discomfort Vomiting SEVERE (Grade 3) Labored breathing Transient hypotension Medical interven
Slide 18: Low Instance of Anaphylaxis
Low Instance of Anaphylaxis* 87% Gastrointestinal Skin Respiratory Immune System 14.2% ALLERGIC REACTIONS SYSTEMIC ALLERGIC REACTIONS More than 1 Body System ANAPHYLAXIS Grade ≥3 0.3% (n=1, Grade 3) 98% mild or moderate *single case (0.3% of subjects) Vickery et al., NEJM, November 18, 2018 (online
Slide 19: Epinephrine Use Was Infrequent
Epinephrine Use Was Infrequent and Not a Surrogate Measure of Anaphylaxis or Systemic Allergic Reaction Severity Percent of Subjects Using Epinephrine Severity of Events Associated with Epinephrine 7.5% ∆ * Includes the single case of severe anaphylaxis Vickery et al., NEJM, November 18, 2018 (onlin
Slide 20: RAMSES Phase 3 Safety Trial Was Consistent with PALISADE
RAMSES Phase 3 Safety Trial Was Consistent with PALISADE
Slide 21: RAMSES Phase 3 Safety Trial of AR101 in Peanut-Allergic Children and Adolescents
Simulated real-world clinical practice and did not require a food challenge Replicated the PALISADE up-dosing period Like PALISADE, prophylactic anti-histamines, to mitigate allergic reactions, were not allowed ~80% of participants completed up-dosing and moved on to maintenance dose in both studies
Slide 22: RAMSES Population Compared to PALISADE
RAMSES Population Compared to PALISADE Baseline Characteristics (Ages 4-17) PALISADE RAMSES Characteristic, n (%) AR101 (n=372) Placebo (n=124) AR101 ( n=337 ) Placebo ( n=168 ) Sex Male 208 (56%) 76 (61%) 218 (64.7%) 102 (60.7%) Age 4-11 years 12-17 years 238 (64%) 134 (36%) 89 (72%) 35 (28%) 226(
Slide 23: AR101 Had a Consistent Safety Profile in Both Phase 3 Trials
AR101 Had a Consistent Safety Profile in Both Phase 3 Trials RAMSES IDE + Up-dosing PALISADE IDE + Up-dosing AR101 (n= 337) Placebo (n=168) AR101 (n=372) Placebo (n=124) Treatment-emergent adverse events 99.1% 94.6% 96.8% 88.7% Epinephrine Use 11.0% 5.4% 10.8% 4.0% Serious adverse events 0.6%* 1.2%*
Slide 24: PALISADE Demonstrated that AR101 Reduces Frequency and Severity of Allergic Reactions
PALISADE Demonstrated that AR101 Reduces the Frequency and Severity of Allergic Reactions to Peanut* *During the DBPCFC at study exit
Slide 25: Understanding PALISADE Efficacy Endpoint: Tolerated Dose
Understanding PALISADE Efficacy Endpoint: Tolerated Dose Subjects needed to react (stop food challenge) at 100 mg peanut protein, or less, at entry Single Tolerated Dose 3 10 30 100 300 600 1000 DBPCFC was done at trial entry and exit; independent assessor at each site Increasing doses of peanut pro
Slide 26: AR101 Significantly Reduced Both Frequency and Severity of Allergic Reactions to Peanut
AR101 Significantly Reduced Both Frequency and Severity of Allergic Reactions to Peanut AR101 Placebo Key Findings Compared to placebo, the AR101 group: Developed fewer moderate and severe symptoms Tolerated more peanut exposure before the onset of symptoms Was more likely to complete the challenge
Slide 27: AR101 Significantly Reduced Epinephrine Use Due to Peanut Exposure
AR101 Significantly Reduced Epinephrine Use Due to Peanut Exposure1 125 mg (~1/2 peanut) is the median eliciting dose in the real world2 1 During the Double-Blind, Placebo-Controlled Food Challenge at study exit 2 The median estimated eliciting dose in real life was 125 mg (N=238 peanut-allergic pat
Slide 28: Clinical Data Show Robust Efficacy and Safety of AR101
Clinical Data Show Robust Efficacy and Safety of AR101 in Highly Sensitive Peanut-Allergic Children and Adolescents AR101 Efficacy at 12-Month DBPCFC in PALISADE1 AR101 Safety Profile in PALISADE1 and RAMSES Robust: Median tolerated dose increased 100-fold, up to ~3-4 peanuts (~6-8 peanuts, cumulati
Slide 29: Looking Forward
Looking Forward
Slide 30: PALISADE Phase 3 Results Published in NEJM
PALISADE Phase 3 Results Published in NEJM (Nov 18, 2018) “…treatment with AR101 resulted in higher doses of peanut protein that could be ingested without dose-limiting symptoms and in lower symptom severity during peanut exposure at the exit food challenge than placebo.” Vickery et al., NEJM, Novem
Slide 31: Aiming to Deliver on Our Promise to the Food Allergy Community
Aiming to Deliver on Our Promise to the Food Allergy Community Next year, AR101 could be the first approved treatment for peanut allergy Biologics License Application (BLA) for AR101 is on track for submission to the U.S. Food and Drug Administration (FDA) in December 2018 as planned; Marketing Auth
Aimmune Therapeutics — Corporate Update (November 2018) on 6ix